Analyst Reco. Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Market Closed - Toronto S.E. Other stock markets 01:29:48 01/06/2024 am IST			5-day change	1st Jan Change
21.06 ^CAD	-0.19%		+2.18%	-7.10%

28/05	Bausch + Lomb's New Intraocular Lens Approved by Health Canada	MT
28/05	Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	07/05	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	06/05	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	02/05	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	22/04	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	05/04	MT
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	26/02	MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating	22/02	MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept	22/02	MT
RBC Trims Price Target on Bausch + Lomb to $19 From $20 Ahead of Q4 2023 Report, Keeps Outperform Rating	09/02	MT
Evercore ISI Downgrades Bausch + Lomb to In Line From Outperform, Adjusts Price Target to $17 From $19	04/01	MT
Stifel Initiates Bausch + Lomb With Hold Rating, $16 Price Target	12/12	MT
Morgan Stanley Trims Price Target on Bausch + Lomb to $16 From $17, Maintains Equal-Weight Rating	04/12	MT
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating	23/23/23	MT
Morgan Stanley Adjusts Price Target on Bausch + Lomb to $18.50 From $20, Keeps Equalweight Rating	13/23/13	MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	04/23/04	MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments	12/23/12	MT
Fitch Assigns Rating to Bausch + Lomb's Secured Term Loan, Secured Bond; Up 1.4%	11/23/11	MT
Barclays Adjusts Price Target on Bausch + Lomb to $19 From $18, Maintains Equalweight Rating	03/23/03	MT
Needham & Co Maintains Hold Rating on Bausch + Lomb After Q2	03/23/03	MT
Toronto Stocks Drop Amid U.S. Credit-Rating Downgrade; Cameco Shares Down	02/23/02	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Analyst Reco.

Filters